Galecto Inc
$ 29.78
-7.80%
26 Feb - close price
- Market Cap 43,730,600 USD
- Current Price $ 29.78
- High / Low $ 32.62 / 29.62
- Stock P/E N/A
- Book Value 5.02
- EPS -12.11
- Next Earning Report 2026-03-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.44 %
- ROE -1.10 %
- 52 Week High 38.33
- 52 Week Low 2.01
About
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company is headquartered in Copenhagen, Denmark.
Analyst Target Price
$32.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-11 | 2025-04-28 | 2025-03-19 | 2024-11-01 | 2024-08-05 | 2024-04-29 | 2024-03-08 | 2023-11-06 | 2023-07-31 | 2023-04-28 | 2023-03-09 |
| Reported EPS | -2.36 | -2.6 | -1.916 | -5 | -3.39 | -0.16 | -0.2 | -0.24 | -0.3 | -0.41 | -0.51 | -0.55 |
| Estimated EPS | None | 0 | None | -2.82 | -3.7 | -0.31 | -0.41 | -0.31 | -0.47 | -0.59 | -0.62 | -0.57 |
| Surprise | 0 | -2.6 | 0 | -2.18 | 0.31 | 0.15 | 0.21 | 0.07 | 0.17 | 0.18 | 0.11 | 0.02 |
| Surprise Percentage | None% | None% | None% | -77.305% | 8.3784% | 48.3871% | 51.2195% | 22.5806% | 36.1702% | 30.5085% | 17.7419% | 3.5088% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-18 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GLTO
2026-02-20 18:51:41
This article highlights bullish sentiments from analysts on two healthcare companies: Establishment Labs Holdings (ESTA) and Galecto (GLTO). TD Cowen's Josh Jennings maintained a Buy rating on ESTA with an $88.00 price target, while LifeSci Capital's Sam Slutsky maintained a Buy rating on GLTO with a $45.00 price target. Both companies have an analyst consensus of Strong Buy, with significant upside implied from their current stock levels.
2026-02-18 18:51:41
UBS has initiated coverage of Galecto (GLTO) with a Buy recommendation, forecasting a 42.45% upside from its current price. Analysts project an average one-year price target of $41.48/share for the company. Institutional ownership in Galecto has increased significantly, with total shares owned by institutions rising by 172.37% in the last three months.
2026-02-17 21:46:57
UBS has initiated coverage on Galecto (GLTO) with a 'Buy' rating and a price target of $45.00. This follows recent positive analyst coverage from Leerink Partners and Guggenheim. Galecto is a clinical-stage biotechnology company focused on developing therapeutics for cancer and liver diseases, including treatments for idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH).
2026-02-16 19:27:21
Galecto (GLTO) recently completed a follow-on public offering, raising approximately US$316.3 million and filing a mixed shelf registration for up to US$150 million. This capital injection and registration provide the company with increased financial flexibility for its pipeline in blood cancers and fibrotic diseases. The article emphasizes that while this significantly improves Galecto's financial standing, investors should consider the continuous risk of dilution.
2026-02-16 09:57:27
Galecto (GLTO) has seen a 21.3% increase in its stock price following a significant $316 million equity raise through a public offering and the filing of a new $150 million mixed shelf registration. This capital injection and future funding flexibility will support its pipeline in blood cancers and fibrotic diseases, shifting the investment focus from balance sheet survival to execution on IND filings for GB3226 and DMR-001 and the build-out of its leadership team, though it also raises concerns about potential shareholder dilution.
2026-02-16 00:27:43
Galecto, Inc. (Nasdaq: GLTO) has successfully closed a public offering of common stock, raising $316 million. Gibson Dunn & Crutcher advised Galecto, while Cooley LLP represented the underwriters. Goodwin Procter LLP served as intellectual property counsel for Galecto.
